![Roger Gunn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Roger Gunn
Directeur/Membre du Conseil chez
Alzheimer's Disease Neuroimaging Initiative
Postes actifs de Roger Gunn
| Sociétés | Poste | Début |
|---|---|---|
Imanova Ltd.
 Imanova Ltd. BiotechnologyHealth Technology Provides research and development solutions in biomarkers & drug development | Corporate Officer/Principal | - |
Alzheimer's Disease Neuroimaging Initiative
 Alzheimer's Disease Neuroimaging Initiative Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a large, ongoing, multi-center, longitudinal observational study launched in 2004 across over 60 clinical sites in the USA. Its primary goal is to support research aimed at developing and validating biomarkers to better understand, diagnose, and treat Alzheimer's disease and related dementias. ADNI collects comprehensive data from participants, including cognitively normal individuals, those with mild cognitive impairment, and dementia patients. The data include clinical assessments, neuroimaging (MRI, PET), biofluid biomarkers (plasma, cerebrospinal fluid), genetics and omics, neuropathology, and remotely collected data. ADNI provides detailed MRI scanner protocols and uses advanced neuroimaging analysis methods such as morphometry, diffusion tensor imaging, functional MRI, and arterial spin labeling. It manages extensive biospecimen collections—blood, urine, cerebrospinal fluid, and brain tissue—with procedures for researchers to request access. ADNI emphasizes rigorous data quality control, documentation, and user support, offering resources like data dictionaries, FAQs, expert consultation, and comprehensive data archives accessible to qualified investigators worldwide. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Imanova Ltd.
Imanova Ltd. BiotechnologyHealth Technology Provides research and development solutions in biomarkers & drug development | Health Technology |
Alzheimer's Disease Neuroimaging Initiative
Alzheimer's Disease Neuroimaging Initiative Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a large, ongoing, multi-center, longitudinal observational study launched in 2004 across over 60 clinical sites in the USA. Its primary goal is to support research aimed at developing and validating biomarkers to better understand, diagnose, and treat Alzheimer's disease and related dementias. ADNI collects comprehensive data from participants, including cognitively normal individuals, those with mild cognitive impairment, and dementia patients. The data include clinical assessments, neuroimaging (MRI, PET), biofluid biomarkers (plasma, cerebrospinal fluid), genetics and omics, neuropathology, and remotely collected data. ADNI provides detailed MRI scanner protocols and uses advanced neuroimaging analysis methods such as morphometry, diffusion tensor imaging, functional MRI, and arterial spin labeling. It manages extensive biospecimen collections—blood, urine, cerebrospinal fluid, and brain tissue—with procedures for researchers to request access. ADNI emphasizes rigorous data quality control, documentation, and user support, offering resources like data dictionaries, FAQs, expert consultation, and comprehensive data archives accessible to qualified investigators worldwide. | Commercial Services |
